News

Quarterly Newsletter of the Board from March of 2025

Small Business Bill of Rights

Pursuant to A.R.S. § 32-1855.01, in connection with an investigation conducted by the Board, at all reasonable times the Board and its authorized agents may examine

Quarterly Newsletter of the Board from July 2023

The Drug Enforcement Administration has made our organization aware that they have eliminated the requirement for DATA-waiver registration for professionals to prescribe buprenorphine to treat opioid

The report of issued permits as determined by A.R.S.§32-1829.01.

Spanish FDA Letter to Healthcare Providers - Breast Implant Safety Updates

FDA Letter to Healthcare Providers - Breast Implant Safety Updates

In accordance with A.R.S.§39-171(A) the Board establishes the point of contact for Public Requests Requests

ADHS: Antivirals Available for Use in Arizona with Tiered Approach

Effective March 1st, New Clinical Alert Activated in the CSPMP regarding the Daily Active MME.